Terms: = Prostate cancer AND B2M, P61769, 567, ENSG00000166710 AND Prognosis
9 results:
1. Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With cancer.
Seow H; Tanuseputro P; Barbera L; Earle C; Guthrie D; Isenberg S; Juergens R; Myers J; Brouwers M; Sutradhar R
JAMA Netw Open; 2020 Apr; 3(4):e201768. PubMed ID: 32236529
[TBL] [Abstract] [Full Text] [Related]
2. Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
Park J; Yoo S; Cho MC; Jeong CW; Ku JH; Kwak C; Kim HH; Jeong H
Urol Int; 2020; 104(3-4):199-204. PubMed ID: 31694041
[TBL] [Abstract] [Full Text] [Related]
3. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract] [Full Text] [Related]
4. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.
Lee KS; Koo KC; Chung BH
Int Urol Nephrol; 2017 Dec; 49(12):2119-2125. PubMed ID: 28905176
[TBL] [Abstract] [Full Text] [Related]
5. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):28-34. PubMed ID: 26754263
[TBL] [Abstract] [Full Text] [Related]
6. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.
Carretero FJ; Del Campo AB; Flores-Martín JF; Mendez R; García-Lopez C; Cozar JM; Adams V; Ward S; Cabrera T; Ruiz-Cabello F; Garrido F; Aptsiauri N
Cancer Immunol Immunother; 2016 Jan; 65(1):47-59. PubMed ID: 26611618
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract] [Full Text] [Related]
8. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract] [Full Text] [Related]
9. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Alexopoulou DK; Papadopoulos IN; Scorilas A
Clin Biochem; 2013 Oct; 46(15):1453-61. PubMed ID: 23499583
[TBL] [Abstract] [Full Text] [Related]
